Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 5, 2013, Pages 1093-1103

  Zárate Blad́es, Carlos R ^a,b   Rodrigues, Rodrigo F ^a   Souza, Patricia R M ^a   Rios, Wendy M ^a   Soares, Luana S ^a   Rosada, Rogério S ^a   Brandão, Izaíra T ^a   Masson, Ana Paula ^a   Floriano, Elaine M ^a   Ramos, Simone G ^a   Silva, Celio L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL EYE INSTITUTE   (United States)

Author keywords

DNA vaccination; Immunotherapy; Inflammation; Th1 Th17 responses; Tuberculosis

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 17;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GAMMA DELTA T LYMPHOCYTE; GENE; HSP65 GENE; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; LYMPHOCYTE COUNT; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TH1 CELL; TH17 CELL; TUBERCULOSIS;

DNA VACCINATION; IMMUNOTHERAPY; INFLAMMATION; TH1/TH17 RESPONSES; TUBERCULOSIS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; GENETIC THERAPY; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-17; LUNG; MICE; MICE, INBRED BALB C; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; TUBERCULOSIS;

EID: 84878813422     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23417     Document Type: Article

References (64)

1. Svenson S, Källenius G, Pawlowski A, Hamasur B. Towards new tuberculosis vaccines. Hum Vaccin 2010; 6:309-17; PMID:20372087.
2. Global Tuberculosis Control WHO. WHO Report 2010. WHO 2010.
3. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. [ix.]. Clin Chest Med 2009; 30:769-82, ix; PMID:19925966.
4. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010; 375:2100-9; PMID:20488518.
5. de Paula L, Silva CL, Carlos D, Matias-Peres C, Sorgi CA, Soares EG, et al. Comparison of different delivery systems of DNA vaccination for the induction of protection against tuberculosis in mice and guinea pigs. Genet Vaccines Ther 2007; 5:2; PMID:17250766.
6. dos Santos SA, Zárate-Bladés CR, de Sá Galetti FC, Brandão IT, Masson AP, Soares EG, et al. A subunit vaccine based on biodegradable microspheres carrying rHsp65 protein and KLK protects BALB/c mice against tuberculosis infection. Hum Vaccin 2010; 6:1047-53; PMID:21157178.
7. Souza PR, Zárate-Bladés CR, Hori JI, Ramos SG, Lima DS, Schneider T, et al. Protective efficacy of different strategies employing Mycobacterium leprae heat-shock protein 65 against tuberculosis. Expert Opin Biol Ther 2008; 8:1255-64; PMID:18694348.
8. Bonato VL, Gonçalves ED, Soares EG, Santos Júnior RR, Sartori A, Coelho-Castelo AA, et al. Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis: activation of CD8+ cells, interferon-gamma recovery and reduction of lung injury. Immunology 2004; 113:130-8; PMID:15312144.
9. Nuermberger E, Tyagi S, Williams KN, Rosenthal I, Bishai WR, Grosset JH. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med 2005; 172:1452-6; PMID:16151038.
10. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel therapeutic vaccine: granulysin and new DNA vaccine against Tuberculosis. Hum Vaccin 2011; 7(Suppl):60-7; PMID:21546794.
11. Zárate-Bladés CR, Bonato VL, da Silveira EL, Oliveira e Paula M, Junta CM, Sandrin-Garcia P, et al. Comprehensive gene expression profiling in lungs of mice infected with Mycobacterium tuberculosis following DNAhsp65 immunotherapy. J Gene Med 2009; 11:66-78; PMID:19035575.
12. Rook GA, Lowrie DB, Hernàndez-Pando R. Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols? J Infect Dis 2007; 196:191-8; PMID:17570105.
13. Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012; 12:581-91; PMID:22790178.
14. Kaufmann SH. Tuberculosis vaccine development: strength lies in tenacity. Trends Immunol 2012; 33:373-9; PMID:22560865.
15. Grange JM, Brunet LR, Rieder HL. Immune protection against tuberculosis - when is immunotherapy preferable to vaccination? Tuberculosis (Edinb) 2011; 91:179-85; PMID:21233019.
16. Doherty TM. Immunotherapy for TB. Immunotherapy 2012; 4:629-47; PMID:22788130.
17. Gupta UD, Katoch VM. Animal models of tuberculosis. Tuberculosis (Edinb) 2005; 85:277-93; PMID:16249122.
18. Ly LH, McMurray DN. Tuberculosis: vaccines in the pipeline. Expert Rev Vaccines 2008; 7:635-50; PMID:18564018.
19. Prabowo SA, Gröschel MI, Schmidt ED, Skrahina A, Mihaescu T, Hastürk S, et al. Targeting multi-drug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 2012; In Press; PMID:23143437.
20. Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci 2004; 9:1701-19; PMID:14977580.
21. Vilaplana C, Montané E, Pinto S, Barriocanal AM, Domenech G, Torres F, et al. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine 2010; 28:1106-16; PMID:19853680.
22. Dlugovitzky D, Notario R, Martinel-Lamas D, Fiorenza G, Farroni M, Bogue C, et al. Immunotherapy with oral, heat-killed, Mycobacterium vaccae in patients with moderate to advanced pulmonary tuberculosis. Immunotherapy 2010; 2:159-69; PMID:20635925.
23. Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008; 63:627-34; PMID:18250184.
24. Vilaplana C, Gil O, Cáceres N, Pinto S, Díaz J, Cardona PJ. Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis. PLoS One 2011; 6:e20404; PMID:21647222.
25. Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400:269-71; PMID:10421369.
26. Ha SJ, Jeon BY, Youn JI, Kim SC, Cho SN, Sung YC. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Ther 2005; 12:634-8; PMID:15690060.
27. Henao-Tamayo M, Palaniswamy GS, Smith EE, Shanley CA, Wang B, Orme IM, et al. Post-exposure vaccination against Mycobacterium tuberculosis. Tuberculosis (Edinb) 2009; 89:142-8; PMID:19264552.
28. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011; 17:189-94; PMID:21258338.
29. Ahn SS, Jeon BY, Kim KS, Kwack JY, Lee EG, Park KS, et al. Mtb32 is a promising tuberculosis antigen for DNA vaccination in pre- and post-exposure mouse models. Gene Ther 2012; 19:570-5; PMID:21956689.
30. Yang XY, Chen QF, Li YP, Wu SM. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One 2011; 6:e23826; PMID:21909406.
31. Guo S, Zhao J. Immunotherapy for tuberculosis: what's the better choice? Front Biosci 2012; 17:2684-90; PMID:22652806.
32. Lockhart E, Green AM, Flynn JL. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006; 177:4662-9; PMID:16982905.
33. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med 2005; 202:1715-24; PMID:16365150.
34. Jung YJ, Ryan L, LaCourse R, North RJ. Properties and protective value of the secondary versus primary T helper type 1 response to airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2005; 201:1915-24; PMID:15955839.
35. Arriaga AK, Orozco EH, Aguilar LD, Rook GA, Hernández Pando R. Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp Immunol 2002; 128:229-37; PMID:11985512.
36. Morais Fonseca D, Rosada RS, e Paula MO, Wowk PF, Franco LH, Soares EG, et al. Experimental tuberculosis: designing a better model to test vaccines against tuberculosis. Tuberculosis (Edinb) 2010; 90:135-42; PMID:20188631.
37. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993; 178:2243-7; PMID:8245795.
38. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178:2249-54; PMID:7504064.
39. Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. Annu Rev Pathol 2012; 7:353-84; PMID:22054143.
40. Jurado JO, Pasquinelli V, Alvarez IB, Peña D, Rovetta AI, Tateosian NL, et al. IL-17 and IFN-γ expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease. J Leukoc Biol 2012; 91:991-1002; PMID:22416258.
41. Cruz A, Fraga AG, Fountain JJ, Rangel-Moreno J, Torrado E, Saraiva M, et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010; 207:1609-16; PMID:20624887.
42. Cruz A, Khader SA, Torrado E, Fraga A, Pearl JE, Pedrosa J, et al. Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J Immunol 2006; 177:1416-20; PMID:16849446.
43. Torrado E, Cooper AM. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev 2010; 21:455-62; PMID:21075039.
44. Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, Doherty TM, et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005; 174:6332-9; PMID:15879133.
45. Hervas-Stubbs S, Majlessi L, Simsova M, Morova J, Rojas MJ, Nouzé C, et al. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. Infect Immun 2006; 74:3396-407; PMID:16714570.
46. Romano M, Roupie V, Wang XM, Denis O, Jurion F, Adnet PY, et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. Immunology 2006; 118:321-32; PMID:16827893.
47. Sable SB, Cheruvu M, Nandakumar S, Sharma S, Bandyopadhyay K, Kellar KL, et al. Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination. PLoS One 2011; 6:e22718; PMID:21799939.
48. Cervantes-Villagrana AR, Hernández-Pando R, Biragyn A, Castañeda-Delgado J, Bodogai M, Martínez-Fierro M, et al. Prime-boost BCG vaccination with DNA vaccines based in β-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model. Vaccine 2013; 31:676-84; PMID:23196205.
49. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330-6; PMID:12612578.
50. Ribeiro-Rodrigues R, Resende Co T, Rojas R, Toossi Z, Dietze R, Boom WH, et al. A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol 2006; 144:25-34; PMID:16542361.
51. Chen X, Zhou B, Li M, Deng Q, Wu X, Le X, et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol 2007; 123:50-9; PMID:17234458.
52. Fedatto PF, Sérgio CA, Paula MO, Gembre AF, Franco LH, Wowk PF, et al. Protection conferred by heterologous vaccination against tuberculosis is dependent on the ratio of CD4(+) /CD4(+) Foxp3(+) cells. Immunology 2012; 137:239-48; PMID:22891805.
53. Kaufmann SH, Väth U, Thole JE, Van Embden JD, Emmrich F. Enumeration of T cells reactive with Mycobacterium tuberculosis organisms and specific for the recombinant mycobacterial 64-kDa protein. Eur J Immunol 1987; 17:351-7; PMID:3106059.
54. Antas PR, Cardoso FL, Pereira KC, Franken KL, Cunha KS, Klatser P, et al. T cell immune responses to mycobacterial antigens in Brazilian tuberculosis patients and controls. Trans R Soc Trop Med Hyg 2005; 99:699-707; PMID:15993451.
55. Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, van Meijgaarden KE, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 2006; 8:2052-60; PMID:16931093.
56. Chegou NN, Black GF, Loxton AG, Stanley K, Essone PN, Klein MR, et al. Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. BMC Infect Dis 2012; 12:10; PMID:22260319.
57. Parida SK, Kaufmann SH. The quest for biomarkers in tuberculosis. Drug Discov Today 2010; 15:148-57; PMID:19854295.
58. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science 2005; 309:264-8; PMID:15933162.
59. Casetti R, Agrati C, Wallace M, Sacchi A, Martini F, Martino A, et al. Cutting edge: TGF-beta1 and IL-15 Induce FOXP3+ gammadelta regulatory T cells in the presence of antigen stimulation. J Immunol 2009; 183:3574-7; PMID:19710458.
60. Davey MS, Lin CY, Roberts GW, Heuston S, Brown AC, Chess JA, et al. Human neutrophil clearance of bacterial pathogens triggers anti-microbial γδ T cell responses in early infection. PLoS Pathog 2011; 7:e1002040; PMID:21589907.
61. Tuomela M, Stanescu I, Krohn K. Validation overview of bio-analytical methods. Gene Ther 2005; 12(Suppl 1):S131-8; PMID:16231045.
62. Rosada RS, de la Torre LG, Frantz FG, Trombone AP, Zárate- Bladés CR, Fonseca DM, et al. Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes. BMC Immunol 2008; 9:38; PMID:18647414.
63. Hsia CC, Hyde DM, Ochs M, Weibel ER; ATS/ERS Joint Task Force on Quantitative Assessment of Lung Structure. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med 2010; 181:394-418; PMID:20130146.
64. Cohen J. Infectious Disease. Approval of novel TB drug celebrated-with restraint. Science 2013; 339:130; PMID:23307714; http://dx.doi.org/10.1126/ science.339.6116.130.